摘要
丙型肝炎目前仍呈全球流行趋势,是严重危害公共卫生及人民健康的疾病。为加速实现WHO 2030年消除丙型肝炎公共卫生危害的战略目标,基于直接抗病毒药物(direct antiviral agents,DAAs)可及性的增加以及国内外不断更新的循证医学证据,中华医学会肝病学分会和感染病学分会组织国内有关专家形成了《丙型肝炎防治指南(2022年版)》。相较于2019年版的丙型肝炎防治指南,本次更新从筛查、诊断、治疗前评估、治疗方案选择及治疗终点等多个方面将推荐意见进一步精炼,这也意味着丙型肝炎的筛查及临床诊治全面进入了高效、简化的时代。本文着重对该指南的更新部分进行解读,归纳整理推荐意见,增进理解,提高实用性,旨在为临床医生丙型肝炎防治提供依据和参考。
Hepatitis C,caused by the hepatitis C virus(HCV),continues to be a global epidemic,posing a significant threat to public health and individual well-being.To accelerate the achievement of the World Health Organization's strategic goal of eliminating the public health impact of hepatitis C by 2030,the Chinese Society of Hepatology and the Chinese Society of Infectious Diseases,based on the increasing accessibility of direct-acting antiviral agents(DAAs)and the constantly evolving evidence from evidence-based medicine both domestically and internationally,have organized relevant experts to develop the Guidelines for the Prevention and Treatment of Hepatitis C(2022 Edition).Compared to the 2019 edition,this update of the hepatitis C guidelines further refines the recommended practices in various aspects,including screening,diagnosis,pre-treatment assessment,treatment regimen selection,and treatment endpoints.This signifies that the screening and clinical management of hepatitis C have entered an era of efficiency and simplification.This article focuses on interpreting the updated sections of the guidelines,summarizing and organizing the recommended practices,enhancing understanding,and improving practicality.It aims to provide basis and reference for the prevention and treatment of viral hepatitis C.
作者
常宇琨
章志丹
Chang Yukun;Zhang Zhidan(Department of Infectious Diseases,the First Hospital Affiliated to the China Medical University,Liaoning Shenyang 110000,China)
出处
《新发传染病电子杂志》
2023年第6期89-92,共4页
Electronic Journal of Emerging Infectious Diseases
基金
辽宁省临床重点专科建设项目(19030010782)。
关键词
丙型肝炎
治疗
预防
指南解读
Hepatitis C
Treatment
Prevention
Guideline interpretations
